Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,012,413
  • Shares Outstanding, K 155,665
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta 2.25
  • Price/Sales 20.62
  • Price/Cash Flow 354.02
  • Price/Book 24.94

Options Overview Details

View History
  • Implied Volatility 86.02% ( -2.08%)
  • Historical Volatility 77.07%
  • IV Percentile 57%
  • IV Rank 60.95%
  • IV High 134.65% on 01/24/24
  • IV Low 10.10% on 06/10/24
  • Put/Call Vol Ratio 0.40
  • Today's Volume 5,719
  • Volume Avg (30-Day) 5,892
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 150,882
  • Open Int (30-Day) 138,886

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.07
  • Number of Estimates 5
  • High Estimate 0.11
  • Low Estimate 0.06
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +177.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.41 +5.89%
on 12/18/24
36.84 -12.60%
on 11/25/24
+1.05 (+3.37%)
since 11/20/24
3-Month
21.16 +52.17%
on 10/07/24
36.84 -12.60%
on 11/25/24
+7.55 (+30.63%)
since 09/20/24
52-Week
12.84 +150.78%
on 02/21/24
36.84 -12.60%
on 11/25/24
+14.99 (+87.10%)
since 12/20/23

Most Recent Stories

More News
TG Therapeutics to Participate in the Evercore HealthCONx Conference

TGTX : 32.20 (+4.04%)
TG Therapeutics Ranked Number One on Deloitte Technology Fast 500â„¢ for Rapid Growth in Biopharmaceutical Sector

TG Therapeutics ranked first on Deloitte Technology Fast 500 due to significant growth from BRIUMVI® MS treatment revenues.Quiver AI SummaryTG Therapeutics, Inc. announced it has been ranked as the fastest-growing...

TGTX : 32.20 (+4.04%)
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500â„¢

TGTX : 32.20 (+4.04%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 32.20 (+4.04%)
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

TGTX : 32.20 (+4.04%)
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

TGTX : 32.20 (+4.04%)
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 32.20 (+4.04%)
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

AAPL : 254.49 (+1.88%)
QCOM : 152.89 (+1.66%)
AMZN : 224.92 (+0.73%)
MNKD : 6.85 (+8.73%)
SNBR : 16.32 (-2.16%)
MANH : 280.26 (-0.81%)
TGTX : 32.20 (+4.04%)
QRVO : 70.85 (+2.98%)
ZM : 85.60 (+1.84%)
WOOF : 3.96 (+0.76%)
VZ : 39.93 (-0.10%)
MCD : 292.68 (+0.84%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.7750 (-6.85%)
LLY : 767.76 (+1.35%)
RHHBY : 34.5000 (+0.76%)
BIIB : 146.47 (-0.62%)
TGTX : 32.20 (+4.04%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.7750 (-6.85%)
LLY : 767.76 (+1.35%)
RHHBY : 34.5000 (+0.76%)
BIIB : 146.47 (-0.62%)
TGTX : 32.20 (+4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 35.17
2nd Resistance Point 33.90
1st Resistance Point 33.05
Last Price 32.20
1st Support Level 30.93
2nd Support Level 29.65
3rd Support Level 28.80

See More

52-Week High 36.84
Last Price 32.20
Fibonacci 61.8% 27.67
Fibonacci 50% 24.84
Fibonacci 38.2% 22.01
52-Week Low 12.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar